10-propargyl-10-deazaaminopterin has been researched along with everolimus in 2 studies
| Studies (10-propargyl-10-deazaaminopterin) | Trials (10-propargyl-10-deazaaminopterin) | Recent Studies (post-2010) (10-propargyl-10-deazaaminopterin) | Studies (everolimus) | Trials (everolimus) | Recent Studies (post-2010) (everolimus) |
|---|---|---|---|---|---|
| 119 | 21 | 85 | 5,631 | 1,289 | 4,579 |
| Protein | Taxonomy | 10-propargyl-10-deazaaminopterin (IC50) | everolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 2 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0022 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for 10-propargyl-10-deazaaminopterin and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for 10-propargyl-10-deazaaminopterin and everolimus
| Article | Year |
|---|---|
StatBite: FDA oncology drug product approvals in 2009.
Topics: Administration, Oral; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cetuximab; Depsipeptides; Drug Approval; Everolimus; Ferrosoferric Oxide; Glutamates; Guanine; Humans; Indazoles; Injections; Panitumumab; Pemetrexed; Pyrimidines; Sirolimus; Sulfonamides; United States; United States Food and Drug Administration | 2010 |